Perry Karsen has more than 30 years of experience in the biopharmaceutical industry and currently serves as Chief Executive Officer of Celgene Cellular Therapeutics (CCT), the cell therapy research and development division of Celgene Corporation. Mr. Karsen has been the CEO of CCT since May 2013, previously serving as Celgene Corporation’s Executive Vice President and Chief Operations Officer. Previously, Mr. Karsen was the President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca plc. He joined Pearl from Celgene, where he was Senior Vice President and Head of Worldwide Business Development, responsible for emerging businesses as president, Asia/Pacific Region, as well as all licensing and strategic collaboration initiatives. Prior to his tenure with Celgene, Mr. Karsen held multiple leadership positions including Vice President, Business Development at Human Genome Sciences, Inc.; Vice President, Strategic Business Analysis and Development at Bristol-Myers Squibb Co.; Senior Vice President, Marketing and Sales at Zimmer, Inc.; Director, Business Development and Representative Director, Japan at Genentech, Inc.; and various domestic and international roles with Abbott Laboratories. Additionally, he was a general partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices. Mr. Karsen currently serves as a member of the board of directors of the Biotechnology Industry Organization (where he also serves on the executive committee), the Life Sciences Foundation, Inc., Agios Pharmaceuticals, Inc. and Alliqua BioMedical, Inc. Mr. Karsen received a Masters of Management from Northwestern University, Kellogg School of Management, a Master in Teaching of Biology from Duke University and a Bachelors of Science in Biological Sciences from the University of Illinois, Urbana-Champaign.

science